PT  - JOURNAL ARTICLE
AU  - Cromer, Deborah
AU  - Reynaldi, Arnold
AU  - Hie, Ainslie
AU  - Schlub, Timothy E.
AU  - Juno, Jennifer A.
AU  - Wheatley, Adam K.
AU  - Kent, Stephen J.
AU  - Khoury, David S.
AU  - Davenport, Miles P.
TI  - Predicting COVID-19 booster immunogenicity against future SARS-CoV-2 variants and the benefits of vaccine updates
AID  - 10.1101/2024.02.08.24302032
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.02.08.24302032
4099  - http://medrxiv.org/content/early/2024/02/09/2024.02.08.24302032.short
4100  - http://medrxiv.org/content/early/2024/02/09/2024.02.08.24302032.full
AB  - The ongoing evolution of the SARS-CoV-2 virus has led to a move to update vaccine antigens in 2022 and 2023. These updated antigens were chosen and approved based on in vitro neutralisation titres against recent SARS-CoV-2 variants. However, unavoidable delays in viral manufacture and distribution meant that the updated booster vaccine was no longer well matched to the circulating SARS-CoV-2 variant by the time of its deployment. Understanding whether the updating of booster vaccine antigens improves immune responses to subsequent SARS-CoV-2 circulating variants is a major priority in justifying future vaccine updates. Here we analyse all available data on the immunogenicity of variant containing SARS-CoV-2 vaccines and their ability to neutralise later circulating SARS-CoV-2 variants. We find that updated booster antigens give a 1.4-fold [95%CI 1.07-1.82] greater increase in neutralising antibody levels when compared with a historical vaccine immunogen. We then use this to predict the relative protection that can be expected from an updated vaccine even when the circulating variant has evolved away from the updated vaccine immunogen. These findings help inform the roll out of future booster vaccination programs.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by Australian NHMRC program grant 1149990 to SJK and MPD, an Australian MRFF award 2005544 to SJK and MPD, MRFF 2015313 to MPD, and MRF2016062 to SJK, MPD, DSK. DC, JAJ, AKW, MPD and SJK are supported by NHMRC fellowships (numbers 1173528, 2009308, 1173433, 1173027 and 1136452 respectively). DSK is supported by a UNSW Scientia Fellowship. JAJ is supported by the Sylvia and Charles Viertel Charitable Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData and code will be made available following publication.